Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Pravastatin
Drug ID BADD_D01824
Description Pravastatin is the 6-alpha-hydroxy acid form of [mevastatin].[T303] Pravastatin was firstly approved in 1991 becoming the second available statin in the United States. It was the first statin administered as the active form and not as a prodrug.[T274] This drug was developed by Sankyo Co. Ltd.; however, the first approved pravastatin product was developed by Bristol Myers Squibb and FDA approved in 1991.[L6142] Pravastatin is made through a fermentation process in which [mevastatin] is first obtained. The manufacturing process is followed by the hydrolysis of the lactone group and the biological hydroxylation with _Streptomyces carbophilus_ to introduce the allylic 6-alcohol group.[T239]
Indications and Usage For the treatment of hypercholesterolemia and to reduce the risk of cardiovascular disease.
Marketing Status Prescription; Discontinued
ATC Code C10AA03
DrugBank ID DB00175
KEGG ID D08410
MeSH ID D017035
PubChem ID 54687
TTD Drug ID D02RQU
NDC Product Code Not Available
Synonyms Pravastatin | Eptastatin | Vasten | CS-514 | CS 514 | CS514 | Lin-Pravastatin | Lin Pravastatin | Lipemol | Liplat | Nu-Pravastatin | Nu Pravastatin | Prareduct | Mevalotin | Pravachol | Elisor | Selektine | Lipostat | Pravacol | Pravasin | Pravastatin Monosodium Salt, (6 beta)-Isomer | Pravastatin Sodium | Pravastatin Sodium Salt | Sodium Salt, Pravastatin | Pravastatin tert-Octylamine Salt | Pravastatin tert Octylamine Salt | Pravastatin, (6 beta)-Isomer | RMS-431 | RMS 431 | RMS431 | SQ-31000 | SQ 31000 | SQ31000 | SQ-31,000 | SQ 31,000 | SQ31,000 | Apo-Pravastatin | Apo Pravastatin | Bristacol
Chemical Information
Molecular Formula C23H36O7
CAS Registry Number 81093-37-0
SMILES CCC(C)C(=O)OC1CC(C=C2C1C(C(C=C2)C)CCC(CC(CC(=O)O)O)O)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Acute myocardial infarctionStromelysin-1P08254T8670210190398; 12485468; 16323393; 9420339
Angina pectorisStromelysin-1P08254T8670210190398; 12485468; 16323393; 9420339
AngioplastyStromelysin-1P08254T8670210190398; 12485468; 16323393; 9420339
ArteriosclerosisLiver carboxylesterase 1P23141T763699420339; 14660992; 14998629; 14984434
Cerebrovascular accidentStromelysin-1P08254T8670210190398; 12485468; 16323393; 9420339
DeathStromelysin-1P08254T8670210190398; 12485468; 16323393; 9420339
Myocardial ischaemiaApolipoprotein EP02649T2168910736278; 7605354
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Pain in extremity15.03.04.0100.000145%
Palpitations02.01.02.0030.000145%
Pancreatitis07.18.01.001--
Panophthalmitis06.04.05.005--Not Available
Paraesthesia17.02.06.005--
Pericardial effusion02.06.01.0020.000072%
Pharyngitis07.05.07.004; 22.07.03.004; 11.01.13.003--
Photosensitivity reaction23.03.09.003--
Pleural effusion22.05.02.0020.000109%
Polymyalgia rheumatica15.06.01.001; 10.04.05.003--Not Available
Premature baby18.04.02.0010.000362%Not Available
Premature delivery18.07.01.0060.000181%
Pruritus23.03.12.001--
Purpura23.06.01.004; 01.01.04.003; 24.07.06.005--
Pyrexia08.05.02.003--
Rash23.03.13.001--Not Available
Renal failure20.01.03.0050.000028%Not Available
Rhabdomyolysis15.05.05.0020.000113%
Rhinitis22.07.03.006; 11.01.13.004--
Sensory loss17.02.07.007--Not Available
Sexual dysfunction21.03.02.003; 19.08.05.002--Not Available
Sinusitis22.07.03.007; 11.01.13.005--
Skin exfoliation23.03.07.0030.000072%Not Available
Sleep disorder19.02.04.001--Not Available
Stevens-Johnson syndrome23.03.01.007; 12.03.01.014; 11.07.01.005; 10.01.03.020--
Subdural haematoma24.07.04.005; 17.08.05.002; 12.01.10.0030.000019%Not Available
Systemic lupus erythematosus23.03.02.006; 15.06.02.003; 10.04.03.0040.000109%Not Available
Tenderness08.01.08.005--Not Available
Tendon rupture15.07.01.008; 12.01.07.0030.000145%Not Available
Tension19.06.02.005--Not Available
The 5th Page    First    Pre   5 6 7    Next   Last    Total 7 Pages